CD19 Antikörper (AA 96-281)
Kurzübersicht für CD19 Antikörper (AA 96-281) (ABIN6941101)
Target
Alle CD19 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 96-281
-
Aufreinigung
- Purified by Protein A/G
-
Immunogen
- Recombinant fragment of human CD19 protein (around aa96-281) (exact sequence is proprietary)
-
Isotyp
- IgG1 kappa
-
-
-
-
Applikationshinweise
-
Positive Control: Raji cells (FACS). Tonsil, Lymph Node or Spleen (IHC).
Known Application: ELISA (For coating, order antibody without BSA), ,Flow Cytometry (1-2 μg/million cells), ,Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT),(Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 200 μg/mL
-
Buffer
- 10 mM PBS with 0.05 % BSA & 0.05 % azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
-
Haltbarkeit
- 24 months
-
-
- CD19 (CD19 Molecule (CD19))
-
Andere Bezeichnung
- CD19
-
Hintergrund
- CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.
-
Molekulargewicht
- 95kDa
-
Gen-ID
- 930
-
UniProt
- P15391
-
Pathways
- Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung
Target
-